Analyze & Strategize
Policybazaar tanks 10% as CEO Yashish Dahiya plans 3.77 mn share sale – Business Standard
Yashish Dahiya intends to offload partial stake via bulks deals on the exchanges He currently holds 2452 million shares in the company Read More
reported by Deepak Korgoankar at Business Standard
RBI Monetary Policy: Repo Rate Headed Towards 6% By February, Says ICICI Bank’s B Prasanna – BQ Prime
Some part of the market are pricing in a repo rate of 7%. This is due to the uncertainty premium, said B Prasanna of ICICI Bank. Read More
reported by Ira Dugal at Bqprime.com
2022 Mahindra Scorpio-N details leaked before official launch – CarToq.com
Mahindra will reveal the much-awaited 2022 Scorpio-N later this month. While the brand has already released a few teaser videos of the upcoming Scorpio-N, the specifications still remain unknown. But some leaked information reveals quite a lot about the upcom? Read More
reported by Shantonil Nag at CarToq.com
Chart Check: Down nearly 30% from highs! This PSU banking stock is a good buy on dips bet – Economic Times
Union Bank of India took support near Rs 33 in May before bouncing back. It rallied nearly 7 per cent in a week which helped the stock to break out from its 20-days moving average, suggesting demand at lower levels. The Relative Strength Index or the RSI is t? Read More
reported by Kshitij Anand at The Times of India
Meet the most robust App for smartest Traders
From the blogs
Has Moody’s rated India fairly visvis peers? – Moneycontrol.com
Even if calendar year growth of 8.8 percent and 8.3 percent are considered, India would still be the fastest-growing economy. India?s adequacy of foreign exchange reserves should be the least of the worries for credit rating agencies. Read More reported by at...
This is Why Bharat Biotech’s Covaxin Failed to be the Hero of India’s Vaccination Story Against Covid News18
Complex processes, scattered production units, need for more safety zones and shortage of skilled staffers are some of the top reasons that restricted Bharat Biotech?s Covaxin from becoming the poster-boy of India?s vaccination story against Covid-19. Read More...
Biocon Biologics gets license to manufacture antibody treatment for Covid Hindustan Times
US-based Adagio Therapeutics has allowed the company to manufacture and commericalise the ADG20-based treatment in India, as well as in select markets. | Latest News India Read More reported by hindustantimes.com at Hindustan...